Results 281 to 290 of about 53,090 (292)

CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer

Cancer Immunology, Immunotherapy, 2018
Qi Jiang, Qiang Fu, Junyu Zhang
exaly  

Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis

Cell
Xinyi Wan, Jialin Song, Lingying Ye
exaly  

Diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19+ tumors

Molecular Oncology, 2017
Zhaohui Wang, Huiping Zhang, David H Sachs   +2 more
exaly  

CD19 Chimeric Antigen Receptor T-Cell Therapy

Grace A. Johnson, Michael D. Jain, Frederick L. Locke   +2 more
openaire   +1 more source

An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis

Cell
Yanan Yue, Kun Pang
exaly  

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Journal of Cellular and Molecular Medicine, 2016
Annette Romanski, Gesine Bug, Erhard Seifried   +2 more
exaly  

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas

Molecular Therapy, 2018
CARLOS A Ramos, Rayne H Rouce, Birju Mehta   +2 more
exaly  

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Molecular Therapy - Methods and Clinical Development, 2019
Maria Castella, Anna Boronat, Raquel Martín-Ibáñez   +2 more
exaly  

Regulation of Antigen Receptor Signaling by the Co-Receptors, CD19 and CD22

2004
LARS NITSCHKE, DOUGLAS T. FEARON
openaire   +1 more source

CD19 as an attractive target for antibody-based therapy

MAbs, 2012
exaly